Company intelligence / Profile preview
Evinature
Israelevinature.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Evinature develops evidence-based nutraceuticals—primarily the CurQD Protocol—for inflammatory bowel diseases. The company’s approach integrates gold-standard clinical research with real-world patient data. Clinical trial results show an ~85% clinical response rate and ~50% remission rate in IBD patients using their lead product. Their pipeline includes discovery-stage small molecules targeting digestive system disorders.
- Therapeutic areas
- Gastroenterology
- Modalities
- Small moleculeNutraceutical (evidence-based supplement)Herbal productNatural remedy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Crohn's & Colitis Foundation partnership to expand access to research-driven nutraceuticals for IBD patients in the US.Exclusive distribution deal with Adacyte Therapeutics to expand global reach of their products.
Beyond the preview
Go deeper on Evinature.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evinature.